Investor Summary

Attention-Deficit/Hyperactivity Disorder (ADHD) affects over 129 million people worldwide, with diagnosis relying heavily on subjective caregiver and teacher reports—leading to overdiagnosis, underdiagnosis, and significant delays in intervention.

At O’VISTA, we’ve developed an objective, non-invasive, and quantifiable solution based on decades of oculomotor neuroscience. ADHD is strongly linked to fronto-striatal circuit dysfunction, which manifests in measurable eye-movement anomalies—particularly:

• Elevated antisaccade error rates (failure to suppress reflexive looks)
• Increased prosaccade latency variability (inconsistent attentional orienting)
• Reduced smooth pursuit gain (impaired visual tracking stability)
• Atypical blink dynamics and fixation instability during sustained attention

These biomarkers reflect core ADHD traits—impulsivity, inattention, and motor restlessness—but unlike behavioral checklists, they are quantifiable, repeatable, and immune to observer bias.

Our platform delivers a 5-minute, game-like assessment via proprietary eye-tracking hardware, generating a standardized neurocognitive profile. This informs:

• Early risk stratification for clinicians
• Personalized therapy pathways via our 50-inch touchscreen + balance board system, which trains inhibitory control, timing precision, and sensory integration
• Progress monitoring for schools, therapists, and parents

O’VISTA does not diagnose ADHD—it provides decision-support data to guide referral, reduce diagnostic uncertainty, and enable earlier behavioral intervention.

We are strategically launching first in the Gulf Cooperation Council (GCC) and Middle East, where:

• Rising awareness of neurodevelopmental disorders is driving demand for objective tools
• Private and public schools are investing in inclusive education infrastructure
• Regulatory pathways for AI-enabled behavioral screening are more agile than in the EU or U.S.
• Cultural preferences for non-pharmaceutical, play-based interventions align with our therapeutic model

Success in this region will generate real-world validation, clinical partnerships, and early revenue—de-risking expansion into Europe, Canada, the U.S., and Australia, where ADHD markets exceed $2.3 billion annually.